Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tunlametinib

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Tunlametinib [inn], If25nr1pv3, 1801756-06-8, Unii-if25nr1pv3, Hl085, Hl-085
    Molecular Formula
    C16H12F2IN3O3S
    Molecular Weight
    491.3  g/mol
    InChI Key
    UFZJUVFSSINETF-UHFFFAOYSA-N
    FDA UNII
    IF25NR1PV3
    Tunlametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK), with potential antineoplastic activity. Upon administration, tunlametinib selectively binds to and inhibits the activity of MEK, preventing the activation of MEK-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a threonine/tyrosine kinase, plays a key role in the activation of the RAS/RAF/MEK/ERK pathway that regulates cell growth. This pathway is often dysregulated in a variety of tumor cell types through BRAF, KRAS and NRAS mutations.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-fluoro-5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide
    2.1.2 InChI
    InChI=1S/C16H12F2IN3O3S/c17-10-5-8(19)1-2-11(10)21-14-9(16(24)22-25-4-3-23)6-12-15(13(14)18)20-7-26-12/h1-2,5-7,21,23H,3-4H2,(H,22,24)
    2.1.3 InChI Key
    UFZJUVFSSINETF-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC(=C(C=C1I)F)NC2=C(C3=C(C=C2C(=O)NOCCO)SC=N3)F
    2.2 Other Identifiers
    2.2.1 UNII
    IF25NR1PV3
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Tunlametinib [inn]

    2. If25nr1pv3

    3. 1801756-06-8

    4. Unii-if25nr1pv3

    5. Hl085

    6. Hl-085

    7. 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-n-(2-hydroxyethoxy)-6-benzothiazolecarboxamide

    8. 6-benzothiazolecarboxamide, 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-n-(2-hydroxyethoxy)-

    9. 4-fluoro-5-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide

    10. Chembl5095241

    11. Hl 085 [who-dd]

    12. Schembl15129499

    13. Gtpl11675

    14. Hl 085

    15. Ufzjuvfssinetf-uhfffaoysa-n

    16. Akos040757035

    17. Example 9 [wo2013107283a1]

    18. Hy-132844

    19. Cs-0204149

    20. 4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-n-(2-hydroxyethoxy)benzo[d]thiazole-6-carboxamide

    2.4 Create Date
    2013-08-05
    3 Chemical and Physical Properties
    Molecular Weight 491.3 g/mol
    Molecular Formula C16H12F2IN3O3S
    XLogP34
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count6
    Exact Mass g/mol
    Monoisotopic Mass g/mol
    Topological Polar Surface Area112
    Heavy Atom Count26
    Formal Charge0
    Complexity496
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1